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ABSTRACT Human immunodeﬁciency virus type 1 (HIV-1) infection of dividing and
nondividing cells involves regulatory interactions with the nuclear pore complex (NPC),
followed by translocation to the nucleus and preferential integration into genomic
areas in proximity to the inner nuclear membrane (INM). To identify host proteins
that may contribute to these processes, we performed an overexpression screen of
known membrane-associated NE proteins. We found that the integral transmem-
brane proteins SUN1/UNC84A and SUN2/UNC84B are potent or modest inhibitors of
HIV-1 infection, respectively, and that suppression corresponds to defects in the ac-
cumulation of viral cDNA in the nucleus. While laboratory strains (HIV-1NL4.3 and
HIV-1IIIB) are sensitive to SUN1-mediated inhibition, the transmitted founder viruses
RHPA and ZM247 are largely resistant. Using chimeric viruses, we identiﬁed the
HIV-1 capsid (CA) protein as a major determinant of sensitivity to SUN1, and in vitro-
assembled capsid-nucleocapsid (CANC) nanotubes captured SUN1 and SUN2 from
cell lysates. Finally, we generated SUN1/ and SUN2/ cells by using CRISPR/Cas9
and found that the loss of SUN1 had no effect on HIV-1 infectivity, whereas the loss
of SUN2 had a modest suppressive effect. Taken together, these observations sug-
gest that SUN1 and SUN2 may function redundantly to modulate postentry, nuclear-
associated steps of HIV-1 infection.
IMPORTANCE HIV-1 causes more than 1 million deaths per year. The life cycle of
HIV-1 has been studied extensively, yet important steps that occur between viral
capsid release into the cytoplasm and the expression of viral genes remain elusive.
We propose here that the INM components SUN1 and SUN2, two members of the
linker of nucleoskeleton and cytoskeleton (LINC) complex, may interact with incom-
ing HIV-1 replication complexes and affect key steps of infection. While overexpres-
sion of these proteins reduces HIV-1 infection, disruption of the individual SUN2 and
SUN1 genes leads to a mild reduction or no effect on infectivity, respectively. We
speculate that SUN1/SUN2 may function redundantly in early HIV-1 infection steps
and therefore inﬂuence HIV-1 replication and pathogenesis.
KEYWORDS CA, HIV-1, SUN1, SUN2, cyclophilin A, early infection, nuclear envelope,
nuclear import, nuclear pore complex, transmitted founder virus
The nuclear envelope (NE) consists of the nuclear lamina and the nuclear membrane,comprising the INM, the perinuclear space (PNS), and the outer nuclear membrane
(ONM), a continuum of the endoplasmic reticulum that spatially separates the nucle-
oplasm from the cytoplasm. The NE serves as a platform for the assembly of large
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protein scaffolds, such as the nuclear pore complexes (NPCs) that allow the transport
of proteins, nucleic acids, and other molecules between the cytoplasm and nucleus.
HIV-1 engages components of the NPC to enable nuclear import and interactions
between HIV-1 CA and the NPC proteins NUP153 (1–4) and NUP358 (3, 5–8), as well as
with the shuttling protein cleavage and polyadenylation speciﬁc factor 6 (CPSF6)
(9–11), and these components may play important roles in this process. Following
nuclear localization, HIV-1 DNA integrates into transcriptionally active chromatin areas,
preferentially in proximity to the NE (12), forming the provirus. The HIV-1 integrase
(IN)-interacting lens epithelium-derived growth factor (LEDGF/p75) (13, 14) and the
CA-interacting CPSF6 (9, 11) also contribute to HIV-1 integration (15–18). However, the
molecular details of how HIV-1 targets preferred sites for provirus establishment and
what the consequences of site selection are for virus replication or latency, as well as
the identity and functions of other participating host proteins, are largely unknown.
Hundreds of proteins have been identiﬁed in enriched NE preparations, yet the
functions of many of them are incompletely understood (19). Included among these are
proteins that comprise the LINC complex, which physically connects proteins that
constitute the nuclear skeleton (e.g., nuclear lamins) with proteins of the cytoskeleton
(e.g., actin, microtubules, and intermediate ﬁlaments) (20). Here, we describe an ectopic
expression screen to identify membrane-associated NE proteins that impact HIV-1
infection. Overexpression of the INM protein Sad1/UNC-84 domain-containing 2 (SUN2)
has recently been described to inhibit HIV-1 infection (21, 22), and we asked whether
other proteins exert a similar activity. In addition to SUN2, we found that overexpres-
sion of SUN1 strongly inhibited HIV-1 in a CA-speciﬁc manner.
Mammalian SUN1 and SUN2 were ﬁrst identiﬁed as homologues of the Caenorhab-
ditis elegans proteins UNC-84A and UNC-84B, respectively, and share a conserved
carboxy-terminal SUN domain that is also found in Sad1 in Saccharomyces cerevisiae
(23). Both proteins interact via their amino-terminal domains with proteins in the
nuclear lamina, such as lamin A (LMNA) (24, 25) and emerin (EMD) (26), and in the PNS
via their carboxy-terminal SUN domains with the Klarsicht-ANC1-Syne-homology
(KASH) domains of nesprin proteins anchored in the ONM (23–25, 27–31). They are
therefore important for several cellular processes, including telomere attachment to the
NE in meiosis and for postmitotic cells (32–36), the DNA damage response (DDR) (37,
38), pre-double-strand break (DSB) and post-DSB homologue pairing (37), the removal
of membranes from chromatin during mitosis (38), positioning of the nucleus, and cell
migration and polarization (23, 39–43). Intriguingly, the greater mobility of damaged
chromatin requires SUN1 and SUN2, since gene knockout of both in murine cells
reduced the mobility of DNA damage foci (44). For SUN1, many splice isoforms have
been described, and some are expressed in a cell-type-dependent manner (45). In
addition, SUN1 can form homodimers or heterodimers with SUN2 (46) and associates
with components of the NPC (47).
Genes encoding NE proteins have been implicated in a variety of inherited disorders
affecting muscle, bones, neurons, and adipose tissue (48). SUN1 and SUN2 gene
dysfunction has been associated with cardiomyopathies and skeletal myopathies (26,
49) and has been observed in certain cancer tissues, suggesting possible tumor
suppressor activity (50, 51). While speciﬁc SUN1 and SUN2 alleles have been directly
connected to Emery-Dreifuss muscular dystrophy (EDMD) and related myopathies (49),
SUN proteins may also have indirect effects in disorders in which the LMNA gene is
mutated. In cells from LMNA-deﬁcient mice, which represent a model for EMDM and the
premature aging Hutchinson-Gilford progeria syndrome (HGPS), SUN1 accumulates to
abnormal levels (52). Surprisingly, mice that are also SUN1 deﬁcient show dramatically
reduced pathological effects associated with the LMNA deﬁciency, suggesting that
elevated SUN1 levels may contribute to the pathological phenotype, by an unknown
mechanism(s) (52). Whether the functions of SUN1 and SUN2 in the DDR are connected
with their roles in myopathies and other laminopathies is currently unresolved.
We demonstrate here that, similar to SUN2 (21), overexpression of SUN1 blocks
nuclear import of HIV-1. HIV-2ROD was also sensitive to SUN1 overexpression; however,
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other lentiviruses, such as simian immunodeﬁciency virus from macaque (SIVmac), were
insensitive. Using chimeric viruses, we mapped the sensitivity determinant to the HIV-1
CA protein. We found that both SUN1 and SUN2 can interact with in vitro-assembled
HIV-1 capsid-nucleocapsid (CANC) nanotubes, potentially reﬂecting a direct interaction
with CA. Mutational analysis demonstrated that the amino-terminal domain of SUN1 is
important for the observed block of HIV-1 infection. While overexpression of SUN1 or
SUN2 blocked HIV-1 infection, gene disruption in THP-1 cells had no (SUN1) or modest
(SUN2) effects on HIV-1 infectivity, possibly indicating redundancy between the two
proteins. We did not observe a connection of endogenous SUN1 or SUN2 expression
with cyclophilin A (CypA)-mediated activities or processes during early HIV-1 infection
steps, as has been proposed for SUN2 (53), suggesting that such effects may be cell
type and/or context speciﬁc.
RESULTS
An overexpression screen identiﬁed the inner nuclear membrane proteins
SUN1 and SUN2 as potential effectors of HIV-1 infection. HIV-1 traverses the NE
through NPCs and integrates preferentially in genomic areas that are topologically
close to the INM (12). We aimed to identify membrane-associated NE proteins that
impact the early stages of HIV-1 infection, and so we performed an overexpression
screen with a series of hemagglutinin (HA)-tagged human NE proteins (Table 1). U87MG
CD4/CXCR4 cells were stably transduced with lentiviral vectors (LVs) encoding the
individual proteins, or with ﬁreﬂy luciferase (LUC) as a negative control, and were
challenged with vesicular stomatitis virus G protein (VSV-G)-pseudotyped green ﬂuo-
rescent protein (GFP)-encoding HIV-1 LV. Infection was measured as the percentage of
TABLE 1Membrane-associated NE proteins analyzed in the overexpression screen
NE
protein Species Taga
Expression in WB
assay (antibody)b
Cell viabilityc
(U87MG
CD4/CXCR4)
Block of HIV-1
(U87MG
CD4/CXCR4)
SUN1 Human N-term HA Yes (anti-HA)  20- to 50-fold
SUN1 Human Untagged Yes (anti-SUN1)  20- to 50-fold
SUN2 Human N-term HA Yes (anti-HA)  3- to 5-fold
SUN2 Human Untagged Yes (anti-SUN2)  3- to 5-fold
NET26 Human N-term HA Yes (anti-HA)  
NET39 Human N-term HA Yes (anti-HA)  
LUMA Human N-term HA Yes (anti-HA)  2-fold
LMNA Human N-term HA Yes (anti-HA)  
EMD Human N-term HA Yes (anti-HA)  
EMDΔLEM Human N-term HA Yes (anti-HA)  
LBR Human N-term HA Yes (anti-HA)  
LULL1 Human N-term HA Yes (anti-HA)  2-fold
LULL1 Human C-term HA Yes (anti-HA)  
TORSA Human N-term HA No (anti-HA)  
TORSA-EQ Human N-term HA No (anti-HA)  
TORSA Human C-term HA Yes (anti-HA)  
TORSA-EQ Human C-term HA No (anti-HA)  
TSPAN5 Human C-term HA No (anti-HA)  
TMEM53 Human C-term HA Yes (anti-HA)  
LAP2 Human C-term HA Yes (anti-HA)  
NURIM Human N-term HA No (anti-HA)  
NURIM Human C-term HA Yes (anti-HA)  
UNCL Rat N-term HA Yes (anti-HA)  
UNCL Human C-term HA No (anti-HA)  
NET3 Human N-term HA No (anti-HA)  
NET3 Human C-term HA No (anti-HA)  
NET31 Human N-term HA No (anti-HA)  
aN-term HA, N-terminal HA; C-term HA, C-terminal HA.
bWB assay, Western blotting assay to detect protein expression with indicated antibody.
cCell viability was visually judged by the appearance of cytopathic effect and cell death in culture, in
comparison to parental U87MG CD4/CXCR4 cells (response set as 100%). , 90 to 100% relative to
response in parental cells; , 50% to 89%; , 0 to 49%. Proteins for which no expression signal was
observed or which showed a strong cytopathic effect were not investigated further.
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GFP-positive cells 2 days after challenge. While most proteins had minimal or no
impact, overexpression of SUN2 resulted in an 5-fold reduction in HIV-1 LV infection
(as described previously) (21, 53), while overexpression of SUN1 inhibited infection by
20-fold (Fig. 1A). We assessed protein expression levels by immunoblotting using an
HA-speciﬁc antibody (Fig. 1B) and conﬁrmed that SUN1 and SUN2 were well expressed.
Indeed, the use of speciﬁc antibodies for SUN1 or SUN2 demonstrated that ectopically
expressed proteins were substantially more abundant than endogenous SUN1/SUN2
(Fig. 1C). Importantly, the strong inhibition of HIV-1 infection by SUN1 was also
observed when we used a full-length nonpseudotyped CXCR4-tropic HIV-1 GFP re-
porter virus (NL4.3GFP), indicating that the route of viral entry does not affect the
magnitude of SUN1-mediated suppression and suggesting an effect downstream of
membrane fusion (Fig. 1D). We also tested untagged SUN1 and observed a similarly
strong block to HIV-1 infection (data not shown).
When we compared the subcellular localization of endogenous SUN1 with ectopi-
cally expressed HASUN1 in U87MG cells, we found that the tagged protein retained a
predominantly perinuclear staining pattern, but with some additional cytosolic local-
ization (Fig. 1E). The SUN1 cDNA that was used in the experiments represents a recently
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identiﬁed splice isoform encoding 888 amino acids (see Material and Methods) (54). We
also tested overexpression of the previously described SUN1 transcript variant 1, which
encodes 785 amino acids (ENST00000401592.5), and found no phenotypic differences
regarding the block to HIV-1 infection (data not shown).
SUN1 overexpression inhibits HIV-1 and HIV-2, but not SIVmac, FIV, EIAV, or
MoMLV. We next investigated the selectivity of the SUN1-induced block for different
retroviruses. U87MG CD4/CXCR4 cells expressing either HASUN1 or HALUC as negative
controls were challenged with serial dilutions of a diverse set of VSV-G-pseudotyped
GFP-encoding retroviral vectors derived from SIVmac, HIV-2ROD, feline immunodeﬁ-
ciency virus (FIV), equine infectious anemia virus (EIAV), or Moloney murine leukemia
virus (MoMLV). SUN1 blocked HIV-1 GFP LV, as well as an LV derived from HIV-2ROD,
whereas SIVmac, FIV, EIAV, and MoMLV were each unaffected by HASUN1 overexpres-
sion (Fig. 2). We observed a similar proﬁle when we compared the infectious titers in
cells overexpressing HASUN2 (data not shown). While HASUN1 overexpression inhib-
ited HIV-1 infection by 20-fold, HIV-2ROD was typically suppressed by 5-fold (Fig. 2),
further indicating the virus substrate speciﬁcity.
Overexpression of SUN1 reduces HIV-1 2-LTR circle accumulation. To determine
the stage of the infection block, we infected HALUC-expressing (negative control) or
HASUN1-expressing U87MG CD4/CXCR4 cells with the VSV-G-pseudotyped HIV-1 GFP
LV and isolated total DNA at various time points postinfection (Fig. 3). Quantitative
TaqMan PCR was then used to determine the copy numbers of GFP or 2-long terminal
repeat (2-LTR) circles, surrogates for early reverse transcription (RT) products and
nuclear import, respectively. To control for plasmid contamination originating from
vector production, we also included samples in which we added the allosteric reverse
transcriptase inhibitor Efavirenz (RTinh). Since LV-mediated transduction was used to
express HASUN1 or HALUC, we used a reporter vector where the 5=- and 3=-LTRs had
been engineered such that only the 2-LTR circles produced by the reporter virus could
be detected (referred to as HIV-1 LV). In a parallel sample, we measured infectivity
by determining the percentage of GFP-expressing cells 48 h after infection. While cells
overexpressing HASUN1 showed substantially reduced permissivity to HIV-1 LV
infection compared to control cells, similar accumulations of the GFP cDNA product
were observed in control and HASUN1-expressing cells, indicating that SUN1 overex-
pression did not suppress reverse transcription (Fig. 3A and B). In marked contrast,
2-LTR circle accumulation decreased by 10-fold in the presence of overexpressed
SUN1, implying a block to nuclear entry or 2-LTR circle formation (Fig. 3C).
Differential susceptibility of HIV-1 strains to SUN1-mediated inhibition. We
next investigated whether the sensitivity toward SUN1-induced block varies among
different HIV-1 strains. For rapid testing without the cumbersome derivation of reporter
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viruses, we applied a strategy of cotransfecting a GFP-encoding minigenome LV with
different full-length HIV-1 molecular clones (55). First, we tested how this strategy
compared with one using a typical GFP reporter virus. In parallel, we transfected 293T
cells with a VSV-G-encoding plasmid and either NL4.3GFP or NL4.3 in combination with
the GFP reporter vector pCSGW. We found that both virus preparations yielded similar
infectious titers on 293T cells (data not shown). In addition, we analyzed inhibition by
overexpressed SUN1 and found that in both cases infectivity was suppressed 20-fold
by SUN1 (Fig. 4A). We then tested infection by the transmitted founder (T/F) viruses
RHPA, SUMA, WITO, THRO, and ZM247 (Fig. 4B and C): SUMA, WITO, and THRO
infectivities were all reduced by 6- to 10-fold by SUN1, whereas RHPA and ZM247
were largely unaffected (Fig. 4B and C). Similar reductions in sensitivities of these T/F
viruses to SUN2-mediated inhibition suggested a common mechanism (data not
shown). These data show that some HIV-1 strains are insensitive to SUN1- or SUN2-
imposed barriers to infection.
HIV-1 capsid protein determines sensitivity to SUN1-mediated inhibition. To
identify the viral determinant(s) dictating sensitivity to SUN1 inhibition, we generated
chimeric proviruses between the sensitive NL4.3 and the insensitive RHPA by using
restriction sites BssHII (5=-LTR), EcoRI (Vpr), and XhoI (Nef), common to both proviruses
(Fig. 5A). We produced GFP-reporter virus constructs by cotransfecting a GFP-encoding
vector as described above and tested infectivity in U87MG CD/CXCR4 cells expressing
HALUC or HASUN1 (Fig. 5B). Replacement of the sequence between the BssHII and
EcoRI sites (encoding Gag, Pol, Vif, and part of Vpr) of NL4.3 with that of RHPA rendered
the resulting virus (BRE) largely insensitive to SUN1 inhibition, while replacement of the
EcoRI-XhoI fragment (encoding part of Vpr, Vpu, Env, Nef, Tat, and Rev) generated a
chimeric virus (ERX) that was still sensitive to SUN1-mediated inhibition (Fig. 5B). We
also observed that HIV-1 containing the CA-p2 of SIVmac (3), like SIVmac, was largely
insensitive to SUN1 or SUN2 (data not shown). We therefore inferred that the insensi-
tivity of T/F viruses to SUN1 or SUN2 may be dictated by CA.
To further delineate the speciﬁc sequence determinant, we generated the Gag-Pol-
encoding vector pCMV-ΔR8.91ExNRA (HIV-1NRA LV), which contained the RHPA Gag
sequence up to the ApaI site (Fig. 5C). While wild-type HIV-1 LV (NL4.3-based) infectivity
was reduced at least 10-fold by SUN1, HIV-1NRA LV was largely resistant (Fig. 5D). When
we compared the RHPA and NL4.3 CA sequences, we found differences at nine
positions, some of which were located proximal to, or within, the cyclophilin-binding
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loop. We therefore introduced single amino acid substitutions into NL4.3 CA to identify
residues that would render the virus insensitive to SUN1-mediated inhibition. We found
that all single amino acid substitutions that did not affect infectivity relative to the wild
type also maintained sensitivity to SUN1 (Fig. 5D and data not shown).
We next engineered some compound mutants and found that the triple mutant
H87QH120NG208A rendered HIV-1 largely insensitive to SUN1-mediated inhibition,
phenocopying HIV-1NRA LV (Fig. 5D). Reciprocally, a triple mutant with the reverse
amino acid substitutions (Q87HN120HA208G) was introduced into HIV-1NRA and
was found to be sufﬁcient to render HIV-1NRA SUN1 sensitive (Fig. 5D). These data
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FIG 4 HIV-1 strains have differential sensitivities to the SUN1-induced block. (A) VSV-G-pseudotyped
NL4.3GFP reporter virus or virus derived by cotransfecting NL4.3 with the GFP LV pCSGW was produced
in parallel and titrated on U87MG CD4/CXCR4 cells expressing HALUC or HASUN1. Percentages of
infected cells were determined 48 h later by ﬂow cytometry. (B) U87MG CD4/CXCR4 cells expressing
HALUC or HASUN1 were infected with the indicated VSV-G-pseudotyped virus produced by cotransfec-
tion with the HIV-1 GFP LV pCSGW, and infectious titers (in infectious units [i.u.] per milliliter) were
determined from 10 viral doses of two independent biological replicates. (C) Presentation of the same
data as shown in panel B, here with the fold changes (HASUN1/HALUC ratios) for mean titers with
standard deviations. Statistical analysis was performed using an unpaired two-tailed t test. ns, not
statistically signiﬁcant; *, P  0.05; ***, P  0.001.
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indicate that speciﬁc residues in HIV-1 CA are involved in conferring sensitivity to
SUN1-induced inhibition.
In vitro-assembled HIV-1 CANC complexes interact with SUN1 and SUN2. Since
HIV-1 sensitivity to SUN1- or SUN2-mediated suppression is determined by speciﬁc
amino acid residues in CA (Fig. 5), we speculated that HIV-1 CA may interact with SUN1
or SUN2. To address this, we analyzed whether ectopically expressed HASUN1 or
HASUN2 could be captured from 293T cell lysates when we used synthetic CANC
nanotubes derived from HIV-1IIIB or the T/F virus RHPA. As a positive control, we
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FIG 5 The determinant for the sensitivity to SUN1-induced inhibition maps to CA. (A) Schematic of the
generation of chimeric viruses between T/F virus RHPA and NL4.3. (B) VSV-G-pseudotyped GFP reporter
viruses were produced by cotransfection with the pCSGW vector, and U87MG CD4/CXCR4 cells were
infected with serial dilutions. Infectious titers were determined from at least three different viral doses,
and mean titers with standard deviations are shown. Representative results of three independent
experiments are shown. Statistical analysis was performed using an unpaired two-tailed t test. ns, not
statistically signiﬁcant; **, P  0.01. (C) Schematic of the generation of the HIV-1NRA Gag-Pol expression
vector. (D) U87MG CD4/CXCR4 cells expressing HALUC or HASUN1 were infected with VSV-G-
pseudotyped HIV-1 wild-type or NRA CA mutant GFP LVs, and mean infectious titers (in infectious units
[i.u.] per milliliter) were determined from 10 different viral doses of three independent biological
replicates. Fold changes in titers and standard deviations are shown. Statistical analysis was performed
using an unpaired two-tailed t test. ns, not statistically signiﬁcant; **, P  0.01; ***, P  0.001.
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expressed HA-tagged CPSF6 (11) in 293T cells and found that CPSF6 interacted efﬁ-
ciently with IIIB and RHPA CANC nanotubes, while the negative control, HALUC, did not
(Fig. 6A and B). Enrichment of proteins through binding to CANC complexes was
controlled internally by our use of parallel samples without added CANC complexes.
Both HASUN1 and HASUN2 interacted with IIIB CANC complexes (Fig. 6A); however,
despite the insensitivity of RHPA infection to SUN1- or SUN2-mediated suppression, its
corresponding CANC complexes also interacted with SUN1 and SUN2 in cell lysates (Fig.
6B). Thus, while SUN1 and SUN2 appear to interact with CANC complexes in vitro, we
were unable to identify a straightforward correlation between such interactions and the
suppression of virus infection in cultured cells (discussed below).
The amino-terminal domain of SUN1 mediates HIV-1 inhibition. To identify
which regions of SUN1 are involved in the inhibition of HIV-1, we generated amino- and
carboxy-terminal deletion mutants. When we analyzed amino-terminal SUN1 deletion
mutants, we found that removal of the ﬁrst 30 (HASUN1Δ30) or 60 (HASUN1Δ60) amino
acids had no substantial effect on the ability of SUN1 to block HIV-1 (Fig. 7A, B, and C).
However, deletion of 90 (HASUN1Δ90), 100 (HASUN1Δ100), or 355 (HASUN1Δ355)
amino acids abrogated HIV-1 suppression (Fig. 7A and B and C). We also observed that
SUN1 mutants lacking regions within the amino-terminal 90 amino acids had higher
expression levels than the wild-type protein (Fig. 7B). Notably, the subcellular localiza-
tions of restricting wild-type HASUN1, HASUN1Δ30, or HASUN1Δ60 were similar to
those of inactive HASUN1Δ90 or HASUN1Δ100, based on immunoﬂuorescence micros-
copy, as they all displayed cytoplasmic and perinuclear staining (Fig. 7D). Deletion of
the carboxy-terminal SUN domain (HASUN1 1-583) did not interfere with the inhibition
of HIV-1 (Fig. 7C), suggesting that the interaction with nesprin proteins within the
perinuclear space and LINC complex formation may not be required for the antiviral
activity observed here.
Signatures of positively selected amino acid residues can be indicative of host-
pathogen interactions (3, 56–59). The ratio of nonsynonymous to synonymous nucle-
otide changes at codon positions can be used to identify positively selected sites. We
aligned SUN1 cDNA sequences from 23 species available from the OrthoMaM database
and analyzed the alignment for positively selected sites by using the Datamonkey
website and the FEL and REL substitution models (60, 61). We were able to identify
signatures of evolutionary pressure within the amino-terminal region of SUN1 that were
suggestive of possible interactions with pathogens (Fig. 7E).
We investigated whether the amino terminus of SUN1 is sufﬁcient to inhibit HIV-1
infection by generating a fusion protein with the MLV restriction factor Friend virus
susceptibility factor 1 (Fv1n). This strategy has been used to analyze CA binding of
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FIG 6 In vitro-synthesized HIV-1 CANC nanotubes capture SUN1 and SUN2 from cell lysates. (A) Cell lysates from
293T cells transfected with HALUC, HACPSF6, HASUN1, or HASUN2 were incubated with in vitro-synthesized CANC
nanotubes before centrifugation through a sucrose cushion and analysis of supernatants and pellets by immuno-
blotting using HA- and CA-speciﬁc antibodies. I, input; S, supernatant; P, pellet. (B) In vitro-synthesized CANC
complexes from RHPA were mixed with cell lysates and analyzed as described for the results shown in panel A.
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FIG 7 The amino-terminal domain of SUN1 is required for the block to HIV-1 and contains signatures of positive
selection. (A) Schematic of analyzed SUN1 deletion mutants. (B) Immunoblot detection of HA-tagged proteins. Total
protein measured by UV activation of the gel served as the loading control. (C) In parallel experiments to those for
the samples shown in panel B, U87MG CD4/CXCR4 cells expressing HALUC, HASUN1, or the indicated SUN1 deletion
mutants were infected with serial dilutions of VSV-G-pseudotyped NL4.3GFP, and infectious titers were determined.
Mean fold changes (relative to untransduced control cells) of at least 10 infectious titers (in infectious units [i.u.] per
milliliter) from three independent experiments and standard deviations are shown. Statistical analysis was performed
using an unpaired two-tailed t test. ***, P  0.001. (D) Immunoﬂuorescence microscopy of U87MG CD4/CXCR4 cells
expressing HASUN1 or HASUN1 deletion mutants stained with an HA-speciﬁc antibody. Nuclei were visualized using
Hoechst stain. Scale bar, 10 m. (E) Positive selection analysis using the FEL (top panel) and REL (bottom panel)
methods.
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certain protein domains by creating Fv1-Cyp (62, 63) or MX2NTD-Fv1 (64) chimeras. As
expected, expression of HAFv1n in U87MG CD4/CXCR4 cells did not inhibit HIV-1
infection (Fig. 8A and B). In contrast, fusing the ﬁrst 130 amino acids of SUN1
(N-terminal domain [NTD]) to the amino terminus of Fv1n (HASUN1NTD-Fv1n) was
sufﬁcient to reduce HIV-1 infection (Fig. 8B), though the extent of inhibition did not
reach the levels observed with HASUN1, most likely due to lower expression levels (Fig.
8A). In conclusion, the data suggest that, similar to SUN2 (21) (data not shown), the
amino terminus of SUN1 is important for the inhibition of HIV-1 infection.
CRISPR/Cas9-mediated SUN2 but not SUN1 gene disruption decreases HIV-1
infectivity. We next sought to address the role of endogenous SUN1 or SUN2 proteins
in HIV-1 infection. We generated single-cell clones of THP-1 cells transduced with
CRISPR/Cas9 LVs expressing individual speciﬁc guide RNAs (gRNAs). We generated two
independent THP-1 single-cell knockout clones for each gene (SUN1g2-5, SUN1g2-7,
SUN2g2-1, and SUN2g3-4). Gene disruption was validated by PCR sequencing across
the gRNA target site as well as by immunoblotting (Fig. 9A and B). All lines were tested
for their susceptibility to infection with VSV-G-pseudotyped NL4.3GFP or chimeric
BREGFP reporter viruses. As shown in Fig. 9C, the depletion of SUN1 had no observable
effect on infection by either virus, whereas the loss of SUN2 resulted in an2- to 3-fold
reduction in HIV-1 infection compared to a CRISPR/Cas9 control cell clone expressing an
irrelevant control gRNA (Fig. 9C). We observed similar infection phenotypes in THP-1
cells that had been differentiated by use of phorbol 12-myristate 13-acetate (PMA)
(data not shown). The infectivity defect in these SUN2 knockout cell clones could not
be explained by defects in cell proliferation, since the infectious titer of a VSV-G-
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FIG 8 Fusion of the amino-terminal SUN1 domain to Fv1 generates a potent HIV-1-inhibiting factor. (A)
Cell lysates of U87MG CD4/CXCR4 cells expressing HALUC (negative control), HASUN1 (positive control),
HAFv1n, or a fusion protein of the amino-terminal 130 amino acids of SUN1 with Fv1n were subjected to
immunoblotting using an HA-speciﬁc antibody; MAPK served as the loading control. (B) Parallel cells (to
those for which results are shown in panel A) were infected with serial dilutions of VSV-G-pseudotyped
NL4.3GFP or BREGFP reporter viruses, and infectious titers were determined. Mean infectious titers (in
infecious units [i.u.] per milliliter) with standard deviations were calculated from six independent viral
doses of two biological replicates. Statistical analysis was performed using an unpaired two-tailed t test.
ns, not statistically signiﬁcant; **, P  0.01.
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pseudotyped MoMLV GFP LV was unchanged in SUN2 knockout cells compared to
control cells (Fig. 9D). We also determined growth kinetics for these cells and did not
observe differences between parental THP-1, control, or SUN2 knockout lines (Fig. 9E).
To identify the step in HIV-1 infection that was impaired in THP-1 cells lacking SUN2
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FIG 9 Gene disruption of SUN2 but not SUN1 reduces infectivity of HIV-1 in THP-1 cells. (A) THP-1 CRISPR/Cas9
single-cell clones transduced to express speciﬁc guide RNAs against SUN1 or SUN2 were generated. Single-cell
cloning followed by PCR-based sequencing across the guide RNA target sites identiﬁed two clones for each
gene in which the open reading frame was disrupted. (B) Disruption of gene expression was veriﬁed by
immunoblotting using SUN1- or SUN2-speciﬁc antibodies; Hsp90 served as the loading control. CRISPR/Cas9
control cells (Cntrl) expressed an unrelated guide RNA. (C) SUN1- or SUN2-depleted cells were infected with
serial dilutions of VSV-G-pseudotyped NL4.3GFP or BREGFP reporter viruses, and infectious titers were deter-
mined. Shown are the fold changes (FC) in mean titers compared to control cells determined from at least 10
viral doses of four independent experiments, with standard deviations. Statistical analysis was performed using
a paired two-tailed t test. ns, not statistically signiﬁcant; *, P  0.05; ***, P  0.001. (D) THP-1 control or SUN2
knockout cells were infected with VSV-G-pseudotyped MoMLV GFP LV. Average infectious titers were deter-
mined from a total of nine viral doses for three biological replicates. Error bars are standard deviations. Statistical
analysis was performed using a nonpaired two-tailed t test. (E) Growth curves of SUN2-depleted THP-1 cells in
comparison to THP-1 parental or control cells. (F) THP-1 control cells or SUN2 g3c4 knockout cells were infected
with DNase-treated VSV-G-pseudotyped NL4.3GFP in the presence or absence of efavirenz (RTinh), and total
DNA was isolated for TaqMan qPCR 6 h (GFP) or 24 h (2-LTR circles) postinfection (p.i.). Fold changes to control
cells in the absence of RTinh were calculated. Data are means from two independent experiments, calculated
from at least four replicates. Error bars are standard deviations. (G) THP-1 control cells, as well as SUN1 or SUN2
knockout cell lines, were infected with VSV-G-pseudotyped HIV-1 or HIVac-1 GFP LV in the presence of 5 M CS
or DMSO vehicle control. Shown are mean infectious titers (in infectious units [i.u.] per milliliter) with standard
deviations from at least six virus doses of two independent experiments. Statistical analysis was performed using
an unpaired two-tailed t test. ns, not statistically signiﬁcant; ***, P  0.001.
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expression, we infected control cells and SUN2 knockout g3c4 cells with DNase-treated
VSV-G-pseudotyped NL4.3GFP and isolated total DNA at 6 or 24 h after infection for use
in a TaqMan quantiative PCR (qPCR). In parallel, we measured infection 2 days postin-
fection by ﬂow cytometry. We found that GFP reverse transcription products were
present at similar levels in control and SUN2 knockout cells 6 h after infection (Fig. 9G).
In contrast, levels of 2-LTR circles were reduced by 2-fold, which correlated with
the decrease in infectivity (Fig. 9G), suggesting that reduced nuclear import underlies
the decreased HIV-1 infectivity. These data support the idea that SUN2 helps
promote the early stages of HIV-1 infection but that the contributions of SUN1 are less
obvious, in that gene disruption does not yield an infection phenotype whereas
purposeful overexpression can be a potent suppressor of infection. It is possible that
SUN1 and SUN2 provide redundant functions for HIV-1 infection; however, simultane-
ous depletion of both proteins can result in mitotic defects and delayed cell prolifer-
ation (38), thus confounding the interpretation of virus infection experiments.
Lahaye et al. reported that in bone marrow-derived dendritic cells from mice, the
infectivity of HIVac-1, an HIV-1 CA mutant that is restricted by CypA (65), is rescued from
this restriction when SUN2 is absent (53). We tested whether infectivity of HIVac-1 could
be rescued in THP-1 cells lacking SUN1 or SUN2. We observed no changes for wild-type
HIV-1 GFP LV in the presence or absence of cyclosporine (CS) (Fig. 9G). The infectivity
of HIVac-1 GFP LV was severely reduced in THP-1 control cells as well as in THP-1 SUN1
or SUN2 knockout cell clones, and CS treatment rescued infectivity in all cases to
infection levels of the wild-type LV (Fig. 9G). We obtained similar results in Jurkat T cell
lines with a SUN1 or SUN2 gene knockout (data not shown). The results suggest that the
CypA effects on HIV-1 infection are not changed by SUN1 or SUN2 gene knockout.
DISCUSSION
We have investigated the impact of several NE proteins on early HIV-1 infection by
using a focused overexpression screen. We found that ectopic expression of UNC-84A/
SUN1 or UNC-84B/SUN2 inhibits HIV-1 infection (Fig. 1). We concentrated our further
studies on the effects of SUN1, since the magnitude of the block was substantially
stronger than that for SUN2 (Fig. 1). We found that ectopically expressed SUN1 localized
to the NE as well as to cytoplasmic regions (Fig. 1E). As a component of the LINC
complex, the amino terminus of SUN1 interacts with proteins of the nuclear lamina,
including lamin A/C, while the carboxy terminus interacts in the perinuclear space with
the nesprin KASH domain (25, 66). Both SUN1 and SUN2 have also been reported to
interact with the INM protein EMD (24). A previous study suggested that EMD serves as
a cofactor for HIV-1 integration (67); however, later studies did not conﬁrm this (68, 69),
and the inability of a LEM domain-deleted EMD to reduce HIV-1 infection can be
considered consistent with the latter reports (Fig. 1).
SUN2 had previously emerged from a functional cDNA screen as a type I interferon
(IFN)-induced gene that blocks HIV-1 infection (22). During the preparation of the
manuscript, three further studies were published reporting a possible role for SUN2 in
early HIV-1 infection steps (21, 53, 70). In agreement with these studies, we did not
observe changes in SUN2 protein levels in type I IFN-treated primary monocyte-derived
macrophages, CD4 T cells, or THP-1 cells (21, 53) (data not shown). Similar to what was
observed by Donahue et al. for SUN2, we found that SUN1 overexpression also reduced
HIV-1 2-LTR circle formation, a surrogate for nuclear import (Fig. 3). However, we did
not ﬁnd that SUN1 expression induced alterations in the morphology of nuclei, as has
been observed for SUN2 (21). We also noted that overexpression of SUN1 was sub-
stantially less cytotoxic than SUN2 (data not shown), indicating differential effects on
general cell function.
In agreement with our results, Donahue et al. showed that SUN2 expression caused
a block to HIV-1NL4.3 and HIV-2ROD, while other strains, in particular many T/F viruses,
were resistant and that the CA protein was likely the viral target (21). We observed a
similar, albeit less broadly distributed, reduced sensitivity of some T/F viruses (i.e., RHPA
and ZM247) to SUN1-mediated inhibition (Fig. 4). Notably, some T/F viruses, including
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RHPA, are hyposensitive to overexpressed MX2, which could indicate that these viruses
generally bypass different cellular factors that are associated with the NE (71). The basis
for the insensitivity of SIVmac and a series of nonprimate retroviruses to human SUN1
and SUN2 overexpression (Fig. 2) is unknown at present, though one possibility is that
these viruses may speciﬁcally interact with the SUN proteins of their natural hosts. Our
results suggest that the amino terminus of SUN1 may have undergone processes of
positive selection during evolution, which could indicate historical instances of species-
speciﬁc viral interactions (Fig. 7E). Finally, it is worth recognizing that despite the
multiple possible redundant cellular functions of SUN1 and SUN2, both proteins may
also have individual roles; for example, while SUN2 has been described as a Rab5-
binding protein involved in endosomal trafﬁcking (72), no such function has been
described for SUN1.
While Donahue et al. propagated an HIV-1 CA mutant (P207S) that was able to
overcome the block induced by SUN2 overexpression, this residue is conserved be-
tween NL4.3 and the T/F virus RHPA and therefore cannot fully explain the insensitivity
of RHPA. Our data suggested that the viral determinant for SUN1- as well as SUN2-
mediated inhibition of HIV-1 infection is located in the HIV-1 CA protein; for example,
HIV-1 harboring the CA from SIVmac was largely insensitive to SUN1 (data not shown).
Accordingly, we concentrated on differences between the RHPA and NL4.3 CA se-
quences and found that amino acid substitutions at positions 87, 120, and 208 in NL4.3
rendered the virus largely insensitive to SUN1 (Fig. 5) or SUN2 (data not shown).
Intriguingly, HIV-2 was also sensitive to SUN1- and SUN2-induced inhibition of infection
(Fig. 2 and data not shown). HIV-1 NL4.3 and HIV-2ROD9 CA amino acid sequences share
only 69% identity, and amino acid residues corresponding to H/Q87, H/N120, and
G/A208 in HIV-1 CA are P86, R118, and N207 in HIV-2ROD9 CA. Whether these residues
are critical for the sensitivity of HIV-2 to SUN1- or SUN2-induced inhibition will require
further investigation, especially given that these residues are conserved between
HIV-2ROD9 and SIVmac, a virus that is insensitive to the SUN1- or SUN2-mediated block
(Fig. 2).
These ﬁndings led us to test for interactions between SUN1 and CA, using in
vitro-assembled CANC nanotubes. We found that SUN1 as well as SUN2 could be
enriched from cell lysates when we used CANC complexes derived from a susceptible
virus strain (Fig. 6). Surprisingly, however, RHPA CANC complexes also precipitated
SUN1 and SUN2, suggesting that the insensitivity of RHPA to SUN1/2 may not simply
be caused by a defect in binding. Similarly, insensitivity to MX2 restriction of certain CA
mutants could not be correlated with defects in MX2 binding in vitro (73). SUN1
interacts with NPCs (47), potentially via (i) the NPC component NUP153 (74), a protein
that is important for HIV-1 nuclear import (2, 11) and whose depletion causes changes
in SUN1 localization (75), and/or (ii) the NUP153-associated protein POM121 (76),
suggesting close proximity between SUN1 and NPCs. It is therefore possible that SUN1
overexpression and (experimentally forced) cytoplasmic accumulation inhibit HIV-1
infection by perturbing the orderly interaction of incoming HIV-1 (CA-containing)
replication complexes with NPC components, or through indirect and unanticipated
effects on NPC function. However, we think it is unlikely that SUN1 overexpression
simply interferes with NUP153 activity, since SIVmac is insensitive to SUN1- or SUN2-
induced inhibition (Fig. 2) but is equally sensitive to RNA interference-mediated
NUP153 depletion as are HIV-2 and HIV-1 (2).
We investigated which domains of SUN1 are important for the inhibition of HIV-1
and found that deletion of the carboxy terminus did not impact the block (Fig. 7). This
suggests that interaction of SUN1 with nesprins in the ONM is not important for HIV-1
inhibition (25). In contrast, deleting 90 amino acids from the amino terminus com-
pletely disrupted the antiviral activity (Fig. 7). Not only was the amino terminus required
for antiviral activity, but it was also sufﬁcient when artiﬁcially fused to Fv1n, generating
a potent HIV-1-inhibiting factor (Fig. 8). Since this chimeric SUN1NTD-Fv1n localizes to
the cytoplasm (data not shown), we inferred that the interaction of the SUN1 amino-
terminal domain with incoming HIV-1 CA can occur in the cytoplasm.
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We addressed the contributions of the endogenous SUN1 and SUN2 proteins to
HIV-1 infection in the myeloid cell line THP-1 (Fig. 9) by generating single-cell clones in
which SUN1 or SUN2 had been knocked out. We found a moderate but reproducible
decrease in HIV-1 infection (but not with MoMLV) in the absence of SUN2, in agreement
with published data using shRNA-mediated SUN2 reduction (65), while there was no
effect on HIV-1 infection in SUN1 CRISPR/Cas9 cells (Fig. 9). The same pattern was also
seen for the chimeric virus BRE, which contains CA from the T/F virus RHPA and has
reduced sensitivity to the block that results from induction of SUN1 or SUN2 overex-
pression. Despite a lack of sensitivity to ectopically expressed SUN2, it is possible that
RHPA CA may still be able to interact with SUN2, since an in vitro interaction between
CANC complexes and SUN2 can occur (Fig. 6). In contrast to other researchers (53), we
found that the lack of SUN2 in THP-1 cells reduced 2-LTR circle accumulation, indicative
of a defect in virus nuclear import (Fig. 9). A series of central questions therefore arises
from this work, including addressing the basis for assay-dependent differences be-
tween viral strains and understanding why infection by viruses such as NL4.3 is reduced
by either SUN2 overexpression or endogenous gene knockout.
Lahaye et al. have proposed that SUN2 promotes CypA-dependent steps during
HIV-1 infection (53). This conclusion was based on two major observations. First, bone
marrow-derived dendritic cells from SUN2/ mice display increased permissivity to
infection by an HIV-1 mutant that is hypersensitive to blockade by CypA (referred to as
HIVac-1) (65). Second, shRNA-mediated depletion of SUN2 in human primary CD4 T
cells decreased permissivity to HIV-1 infection and the inhibition of CypA function only
had a minor effect in SUN2-depleted cells, while in control cells CypA inhibition caused
a signiﬁcantly greater reduction in HIV-1 infection (65). We challenged this conclusion
by infecting THP-1 SUN1 or SUN2 knockout cells with either wild-type HIV-1 GFP LV or
HIVac-1 in the presence or absence of the cyclophilin inhibitor CS. In all cases,
irrespective of SUN1/2 status, the infectivity of HIVac-1 was substantially reduced in the
absence of CS, and addition of CS rescued infectivity to levels comparable to those of
the wild type (Fig. 9). In agreement with our results, a recent study found no connection
between SUN2 and CypA, even in primary CD4 T cells (70). While there may be
differences between primary CD4 T cells and immortalized cell lines, we conclude that
gene disruption of SUN1 or SUN2 in the studied cell lines has no impact on the
CypA-mediated events during early HIV-1 postentry steps. To address the important
question of functional redundancy between SUN1 and SUN2, we attempted simulta-
neous depletion of both genes; however, severe effects on cell proliferation were
evident (38), and we were unable to generate double-knockout cell lines. Therefore, we
have not yet been able to determine whether SUN1 and SUN2 have redundant
activities in the context of HIV-1 postentry steps.
In conclusion, we propose that the amino-terminal domains of SUN1 and SUN2 may
interact with incoming HIV-1 subviral CA-containing replication complexes and facili-
tate steps during early HIV-1 infection, possibly in a redundant fashion. The CA protein
has been demonstrated to be important for HIV-1 nuclear import (3, 11, 77, 78), and we
showed here that the amino-terminal domain of SUN1 interacts with HIV-1 in a
CA-speciﬁc manner. Because the endogenous SUN1 and SUN2 proteins localize to the
INM and their amino termini face the nucleoplasm, we hypothesize that their interac-
tions with nuclear CA-containing nucleoprotein complexes (79–81) may contribute to
nuclear import and/or targeting of the HIV-1 integration machinery to the host cell
genome.
MATERIALS AND METHODS
Cells. THP-1 cells were grown in RPMI 1640 GlutaMax medium (Gibco) supplemented with 10%
heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, and 100 g/ml streptomycin. For differenti-
ation, THP-1 cells were treated with 25 ng/ml PMA (Sigma-Aldrich) overnight. 293T and U87MG
CD4/CXCR4 cells (82) were grown in Dulbecco’s modiﬁed Eagle medium (DMEM GlutaMax; Gibco) with
10% heat-inactivated FCS and penicillin-streptomycin.
Plasmids, cDNAs, and viral vectors. cDNAs for EMD and EMDΔLEM were kind gifts of Juan
Martin-Serrano (King’s College London). SUN1, SUN2, and LMNA cDNAs were derived from THP-1 total
RNA using the SuperScript III One-Step RT-PCR system with Platinum Taq DNA polymerase (ThermoFisher
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Scientiﬁc) cloned into TopoTA pCR2.1 (ThermoFisher Scientiﬁc) and subcloned into pCSxW (83). The
SUN1 isoform cloned and used in the assays encoded 888 amino acids and represents a novel
isoform with closest similarity to isoform ENST00000405266 but containing an additional exon
(ENSE00003501736), which has been described in other alternatively spliced SUN1 isoforms (e.g.,
ENST00000429178.5) and with a described common single nucleotide polymorphism (SNP; rs6461378),
leading to the H118Y amino acid change. The LULL1, LBR, NET26, NET39, and LUMA cDNAs were a gift
from Rose Goodchild (KU Leuven) and Barbara Klupp (84) and were cloned into pCSxW following PCR
ampliﬁcation. HAFv1n cDNA was ampliﬁed from pEXN-Fv1n (62) by PCR and inserted into pCSxW. To
generate HASUN1NTD-Fv1n the fragment encoding the SUN1 amino terminus (amino acids 1 to 130) was
subcloned into pCSxW-HAFv1n. For overexpression studies, proteins were usually expressed as amino-
terminal HA-tagged fusion proteins from pCSxW-HA (83).
VSV-G pseudotyped GFP-encoding HIV-1 vectors were produced using pCMV-ΔR8.91 or the deriva-
tive thereof, pCMV-ΔR8.91Ex-NRA. pCSGW, and pMD.G have been described previously (3). pCMV-
ΔR8.91Ex containing a NotI site upstream of Gag and a unique ApaI site in Gag was a kind gift by Yasuhiro
Ikeda (Mayo Clinic, Rochester, MN, USA). To generate pCMV-ΔR8.91Ex-NRA, the RHPA Gag sequence was
ampliﬁed using forward primer 5=-AT CGC GGC CGC TGG TGA GAG ATG GGT GCG AGA GCG TCG GTA TTA
AGC GGG GG-3= (underlining in the primer sequence indicates the NotI restriction site, and italics indicate
the start codon) and a reverse primer downstream of the ApaI site in RHPA and inserted between
NotI/ApaI sites in pCMV-ΔR8.91Ex.
pCSGW was generated by site-directed mutagenesis, using 3=-LTR forward/reverse primers 5=-ACT
GGA AGG GCT TTA AGA CTC CCA ACG AAG AC-3=/5=-TTC GTT GGG AGT CTT AAA GCC CTT CCA GTC CC-3=
and 5=-LTR primers 5=-ATC CCT CAG ACC GAA AAA GTC AGT GTG GAA AAT C-3=/5=-TCC ACA CTG ACT
TTT TCG GTC TGA GGG ATC TCT AG-3=. To generate a 2-LTR standard plasmid, a PCR amplicon using
forward/reverse primers 5=-AAC TAG AGA TCC CTC AGA CCC TTT T-3=/5=-CTT GTC TTC GTT GGG AGT GAA
TT-3= was generated from total DNA of cells transduced with pCSGW-derived vector and inserted into
pCR2.1-TOPO. The generated plasmid was used to make a standard speciﬁc for pCSGW by site-
directed mutagenesis.
Full-length HIV-1 GFP reporter virus preparations were generated from pNLENG-IRES-Nef (3, 85).
Plasmids encoding NL4.3/RHPA chimeric viruses were generated by subcloning BssHII-, EcoRI-, and
XhoI-digested RHPA plasmid fragments into pNL4.3. NL4.3 encoding Renilla luciferase in place of Nef has
been described before (82). Plasmids to generate viral GFP reporter vectors of SIVMAC, HIV-2ROD, FIV, EIAV,
and MoMLV have been described before (86).
To generate CRISPR/Cas9 cells, gRNA encoding oligonucleotides (MWG/Euroﬁns) were annealed and
cloned into BsmBI-linearized plentiCRISPRv2 according to reported guidelines (Addgene) (87, 88).
Oligonucleotides (forward/reverse) for cloning plentiCRISPRv2-SUN1g1were 5=-CAC CGT ACG TGT AGC
CCG TGT TCT C-3=/5=-AAA CGA GAA CAC GGG CTA CAC GTA C-3=; for SUN1g2, 5=-CAC CGT CGT GGC CAG
GCG CAA ACT A-3=/5=-AAA CTA GTT TGC GCC TGG CCA CGA C-3=; for SUN2g1, 5=-CAC CGC GCC TCA CGC
GCT ACT CCC A-3=/5=-AAA CTG GGA GTA GCG CGT GAG GCG C-3=; for SUN2g2, 5=-CAC CGA ACT GCA TGG
TGA CGC CAA C-3=/5=-AAA CGT TGG CGT CAC CAT GCA GTT C-3=; for SUN2g3, 5=-CAC CGC TCC TCT GAG
GAC GAC TAC G-3=/5=-AAA CCG TAG TCG TCC TCA GAG GAG C-3=.
SIVmac VLP, lentiviral vector, and HIV-1 production. 293 T cells grown in 10-cm plates were
transfected at a conﬂuence of 75% with 4.5 g HIV-1 viral vector plasmid pCSxW, 3 g pCMVΔR8.91,
and 3 g pMD.G, using 4 g polyethylenimine (PEI) per g DNA in 1 ml of Opti-MEM (Gibco) per plate.
For SIVmac virus-like particle (VLP) production, 5 plates were transfected with 8 g Gag-Pol-encoding
plasmid pSIV3 (89) and 2 g pMD.G per plate. For VSV-G-pseudotyped full-length HIV-1 production, 8
g HIV-1 GFP reporter viral plasmid and 2 g pMD.G were transfected per plate. To generate full-length
laboratory strains HIV-1NL4.3, HIV-1IIIB, or HIV-1 transmitted/founder RHPA, SUMA, WITO, THRO or ZM247
with a copackaged GFP lentivirus (LV) minigenome, 4.5 g pCSGW was cotransfected with 3 g
full-length viral plasmid and 3 g pMD.G. For all viral production, medium was changed 24 h posttrans-
fection, the viral supernatant was harvested at 48 h and 72 h posttransfection, and collections were
pooled and passed through a 0.45-m ﬁlter (Rotilabo KH55.1, Roth). Depending on the experiment, viral
vector supernatants were subjected to sucrose cushion puriﬁcation as described previously (90). For
SIVmac VLP production, 30 ml viral supernatant was sucrose concentrated and resuspended in 300 l
RPMI 1640 containing penicillin-streptomycin.
Generation of CRISPR/Cas THP-1 cell clones. THP-1 CRISPR/Cas9 cells were generated by trans-
duction with VSV-G-pseudotyped HIV-1 LV produced using pCMV-ΔR8.91, pMD.G, and plentiCRISPRv2
(Addgene) (87, 88). Transduced cell populations were selected with 2 g/ml puromycin (Sigma-Aldrich)
for 2 weeks. Single-cell clones were generated by limiting dilution in 96-well plates and grown for at least
2 weeks in the absence of puromycin. Cell clones without protein expression were determined by
immunoblotting using SUN1- or SUN2-speciﬁc antibodies. To verify gene disruption, we sequenced PCR
amplicons over the gRNA target site generated from isolated total genomic DNA of selected clones. The
following primer pairs (forward/reverse) were used: for SUN1g1, 5=-ACA CTG CTG CTG GCC GTG TTT CCT
G-3=/5=-AGT CAC CAG GAT GAA CAG ATT CAG-3=; for SUN1g2, 5=-AGT AAT AGT TGC TCT TGA AAA TCC
AC-3=/5=-TCG AGA CAG GGT GCG GCT TTA CAG AC-3=; for SUN2g1 5=-ACA GTG CAG GGG TGC TTC ACA
GAT C-3=/5=-TGC TGT GTG CTC ATA CAC ATG GAG C-3=; for SUN2g2, 5=-TTG TAA AGT TTG AAT GTG
GC-3=/5=-AAG TCC TCG GTG GCC TTG CG-3=; for SUN2g3 5=-TGT TGG CCT TAG GTT GCC ATA G-3=/5=-AGC
ACC CAC CAT GTG TGA GC-3=. As negative controls, we used either a THP-1 single-cell clone that has
been described before (91) or parental THP-1 cells.
Infections. U87MG CD4/CXCR4 or THP-1 cells were plated at 8  104 or 1  105 cells, respectively,
in 96-well plates. Cells were infected for 24 to 72 h before harvest, ﬁxed in PBS plus 4% paraformaldehyde
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(PFA), and analyzed by ﬂow cytometry using a FACSVerse system (BD Biosciences). Infectivities were
determined as the percentage of GFP cells. Virus titrations were usually performed with 3-fold serial
dilutions of the viral supernatant. CS (Sandimmune, Novartis Pharmaceutical Corporation) was used at 5
M in dimethyl sulfoxide (DMSO) and added at the time of infection with the reporter virus. DMSO was
used as the vehicle control at the same concentration.
Immunoblotting and antibodies. Proteins were separated in SDS-polyacrylamide gels by using the
Mini-Protean Tetra cell system (Bio-Rad) at 120 V for 1 h and transferred to nitrocellulose or polyvi-
nylidene diﬂuoride membranes. Antibodies used in immunoblotting were the following: rat anti-HA
coupled to peroxidase-conjugated monoclonal antibody 3F10 (1:5,000; Roche), rabbit anti-mitogen-
activated protein kinase (anti-MAPK; Erk1/2; 1:1,000; Cell Signaling), mouse anti-HIVp24 (24.2) (92),
monoclonal rabbit anti-SUN1 GTX63537 (1:1,000; Genetex), monoclonal rabbit anti-SUN2 EPR6557
(1:1,000; Abcam), rabbit polyclonal anti-Hsp90 antibody H-114 (1:3,000; sc-7947; Santa Cruz Biotechnol-
ogy), and mouse anti-alpha-tubulin (1:3,000; Sigma-Aldrich). Secondary antibodies were goat anti-mouse
IgG horseradish peroxidase (HRP) linked (1:10,000; Pierce, Thermo Scientiﬁc) and goat anti-rabbit IgG
HRP-linked (1:10,000; Cell Signaling, NEB). Total protein input was determined via UV activation of
Mini-Protean TGX stain-free reagent (Bio-Rad).
Protein expression and puriﬁcation. HIV-1 CANC DNA sequences (Gag residues 133 to 432) derived
from wild-type HIV-1IIIB or from the founder virus strain RHPA were cloned into the pST39 vector (93) by
using NdeI and BamHI sites. Proteins were expressed in Escherichia coli Rosetta (DE3) cells (Merck
Millipore) following the protocol described by Lemke et al. (94) with some modiﬁcations. Brieﬂy, a 20-ml
overnight preculture was added to 300 ml of fresh Luria broth and grown for 4 h at 37°C. Then, three
fractions of 100 ml of this culture were added to 1 liter of fresh broth and grown at 37°C until the
optical density at 600 nm was 0.6. Protein expression was induced with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) treatment for 5 h at 30°C. Cells were collected by centrifugation at 3,500
rpm for 20 min and lysed by sonication in a 50 mM Tris-HCl (pH 8.3) buffer containing 1 M NaCl, 10%
glycerol, 1 mM EDTA, 10 mM dithiothreitol (DTT), and 1 mM phenylmethylsulfonyl ﬂuoride (PMSF). Cell
debris was removed by centrifugation at 30,000  g for 20 min, and the supernatant was diluted with
lysis buffer without salt to a ﬁnal concentration of 0.5 M NaCl. Nucleic acids were removed by adding 0.11
volumes of 2 M ammonium sulfate and the same volume of 10% PEI (pH 8.0), stirring the sample for 20
min at 4°C, and ﬁnally centrifuging at 30,000  g for 20 min. CANC was precipitated from the resulting
supernatant by adding 0.35 volumes of saturated ammonium sulfate followed by 10,000  g centrifu-
gation for 15 min. Pelleted protein was resuspended in a 50 mM morpholineethanesulfonic acid (MES;
pH 6.5) buffer containing 0.5 M NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF and then
diluted with the same buffer without salt to a ﬁnal concentration of 0.2 M NaCl. The sample was cleared
by centrifugation, and CANC was puriﬁed by cation-exchange chromatography on a 5-ml HiTrap SP HP
column (GE Healthcare) using a 50 mM MES (pH 6.5) buffer containing 0.2 M NaCl, 10% glycerol, 1 mM
EDTA, 1 mM DTT, and 1 mM PMSF as equilibration buffer. CANC was eluted with a linear gradient
resulting from mixing the equilibration buffer with a 50 mM MES (pH 6.5) buffer, containing 1 M NaCl,
10% glycerol, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF. Fractions containing the protein were pooled,
and CANC was precipitated by adding 1 volume of saturated ammonium sulfate. Finally, the protein was
resuspended to a ﬁnal concentration of 200 M in a 30 mM MES (pH 6) buffer containing 0.5 M NaCl,
1 mM EDTA, and 10 mM DTT.
In vitro assembly of CANC complexes. Puriﬁed CANC was assembled by mixing the protein to a
40 M ﬁnal concentration with 5 M TG50 oligonucleotide (5=-TGT GTG TGT GTG TGT GTG TGT GTG TGT
GTG TGT GTG TGT GTG TGT GTG TG-3=) in a 50 mM Tris-HCl (pH 8) buffer containing 100 mM NaCl and
incubated overnight at room temperature.
CANC pulldown. 293T cells transfected with pCSxW expressing HA-tagged ﬁreﬂy luciferase, CPSF6,
or wild-type SUN1 or SUN2 proteins were lysed with hypotonic lysis buffer (10 mM Tris-HCl [pH 8], 10 mM
KCl, 1 protease inhibitor cocktail [Roche]) using a Dounce homogenizer. Lysates were cleared by
centrifugation at 20,000  g for 15 min. For pulldown experiments, 200 l of cell lysate was mixed with
either 40 l of 40 M assembled CANC (an input sample was taken from this mix) or 40 l of CANC
binding buffer (50 mM Tris-HCl [pH 8], 100 mM NaCl) containing 5 M TG50 and incubated at room
temperature for 1 h. The mixture was then overlaid onto a 250 l 70% sucrose cushion and centrifuged
at 15,000  g for 10 min. A sample of the supernatant was withdrawn for further analysis, and the pellet
was washed with 500 l of wash buffer (50 mM Tris-HCl [pH 8], 50 mM NaCl, and 5 mM KCl), and
centrifuged again at 10,000  g for 5 min. Finally, the pellet was resuspended in 50 l of 1 SDS-PAGE
loading buffer. Input, supernatant, and pellet fractions were analyzed by immunoblotting using appro-
priate antibodies.
TaqMan qPCR. U87MG CD4/CXCR4 HA-LUC or HA-SUN1 were seeded at 2  105 cells per well in
6-well plates and infected the next day in triplicate with VSV-G-pseudotyped HIV-1 GFP LV containing the
pCSGWminigenome in the presence or absence of the reverse transcription inhibitor efavirenz (5 M;
brand name Sustiva, 30-mg/ml oral solution; Bristol Meyer Squibbs) to control for plasmid contamination.
THP-1 CRISPR/Cas9 control or SUN2 knockout g3c4 cells were seeded at 6  105 cells per well in 6-well
plates and infected the next day in triplicate with VSV-G-pseudotyped NL4.3GFP in the presence or
absence of efavirenz as described above. Total DNA was isolated at the indicated time points postin-
fection using the QiaAmp extraction kit (Qiagen), and percentages of GFP cells were determined by
ﬂow cytometry 2 days postinfection. TaqMan qPCR was performed using GFP forward/reverse primers
5=-CAA CAG CCA CAA CGT CTA TAT CAT-3=/5=-ATG TTG TGG CGG ATC TTG AAG-3= and the probe
6-carboxyﬂuorescein (FAM)–5=–CCG ACA AGC AGA AGA ACG GCA TCA A–3=–5-carboxytetramethyl-
rhodamine (TAMRA), and for 2-LTR circle primers 5=-AAC TAG AGA TCC CTC AGA CCG AAA A-3=/5=-CTT
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GTC TTC GTT GGG AGT CTT AA-3= (speciﬁc for pCSGW) and probe FAM-5=-CTA GAG ATT TTC CAC ACT
GAC-3=-TAMRA (95). Samples were normalized to the input total DNA concentration. TaqMan qPCRs were
performed using the Applied Biosystems 7500 real-time PCR system.
Positive selection analysis. The sequences for SUN1 positive selection analysis were derived from
the OrthoMaM website (v9.0) and aligned manually using Se-Al (http://tree.bio.ed.ac.uk/software/seal/)
before subjecting the data to analysis using the HyPhy package (96) on the Datamonkey website (60, 61).
For each alignment, a substitution model selection was performed and the recommended model was
applied. Positive selection analysis was performed using the FEL and REL methods, with a signiﬁcance
level of P  0.05 for FEL and a Bayes factor of 50 as the cutoff for REL. SUN1 sequences for the
alignment were from Homo sapiens, Pan troglodytes, Pongo pygmaeus, Nomascus leucogenys, Papio
anubis, Macaca mulatta, Callithrix jacchus, Canis familiaris, Felis catus, Myotis lucifugus, Ailuropoda mela-
noleuca, Equus caballus, Otolemur garnettii, Ictidomys tridecemlineatus, Mustela putorius furo, Monodelphis
domestica, Loxodonta africana, Mus musculus, Rattus norvegicus, Ornithorhynchus anatinus, Chlorocebus
sabaeus, Ovis aries, Dasypus novemcinctus.
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